“Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients With Active Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study”. SKIN The Journal of Cutaneous Medicine 7, no. 2 (March 13, 2023): s114. Accessed October 6, 2025. https://skin.dermsquared.com/skin/article/view/1964.